Adia Med to Expand Treatment Offerings with Therapeutic Plasma Exchange (TPE) Across All Future Full Clinic Locations
Adia Nutrition (OTC: ADIA) has announced that its subsidiary, Adia Med, will incorporate Therapeutic Plasma Exchange (TPE) treatment across all future full clinic locations in the United States, with its current location already offering this service. TPE uses apheresis machines to remove and replace patient plasma, targeting harmful substances in the bloodstream.
The clinics will utilize the same equipment used for Hematopoietic Stem Cell Transplantation (HSCT), making Adia Med one of only three clinic networks in the U.S. with this technology. The treatment shows promise for various conditions, including Alzheimer's disease, where studies indicate TPE combined with albumin replacement can slow cognitive decline.
The national average cost for TPE ranges from $4,000 to $6,000 per patient. With Florida's large retiree population of over 4.5 million residents aged 65 and older, Adia Med sees significant market potential, particularly for age-related conditions and autoimmune disorders.
Adia Nutrition (OTC: ADIA) ha annunciato che la sua filiale, Adia Med, integrerà il trattamento di Scambio Terapeutico di Plasma (TPE) in tutte le future sedi cliniche complete negli Stati Uniti, con la sua attuale sede che già offre questo servizio. Il TPE utilizza macchine di aferesi per rimuovere e sostituire il plasma dei pazienti, mirato a sostanze nocive nel flusso sanguigno.
Le cliniche utilizzeranno lo stesso equipaggiamento impiegato per il Trapianto di Cellule Staminali Ematopoietiche (HSCT), rendendo Adia Med una delle sole tre reti cliniche negli Stati Uniti con questa tecnologia. Il trattamento mostra promesse per varie condizioni, inclusa la malattia di Alzheimer, dove studi indicano che il TPE combinato con la sostituzione dell'albumina può rallentare il declino cognitivo.
Il costo medio nazionale per il TPE varia da $4.000 a $6.000 per paziente. Con la grande popolazione di pensionati della Florida, che conta oltre 4,5 milioni di residenti di età pari o superiore a 65 anni, Adia Med vede un significativo potenziale di mercato, in particolare per le condizioni legate all'età e i disturbi autoimmuni.
Adia Nutrition (OTC: ADIA) ha anunciado que su subsidiaria, Adia Med, incorporará el tratamiento de Intercambio Terapéutico de Plasma (TPE) en todas las futuras ubicaciones de clínicas completas en los Estados Unidos, con su ubicación actual ya ofreciendo este servicio. El TPE utiliza máquinas de aferesis para eliminar y reemplazar el plasma del paciente, enfocándose en sustancias nocivas en el torrente sanguíneo.
Las clínicas utilizarán el mismo equipo utilizado para el Trasplante de Células Madre Hematopoyéticas (HSCT), convirtiendo a Adia Med en una de las tres únicas redes clínicas en los EE. UU. con esta tecnología. El tratamiento muestra promesas para diversas condiciones, incluida la enfermedad de Alzheimer, donde estudios indican que el TPE combinado con la sustitución de albúmina puede ralentizar el deterioro cognitivo.
El costo promedio nacional para el TPE varía de $4,000 a $6,000 por paciente. Con la gran población de jubilados de Florida, que supera los 4.5 millones de residentes de 65 años o más, Adia Med ve un significativo potencial de mercado, particularmente para condiciones relacionadas con la edad y trastornos autoinmunes.
아디아 뉴트리션 (OTC: ADIA)은 자회사인 아디아 메드가 미국의 모든 향후 전체 클리닉 위치에서 치료용 혈장 교환(TPE) 치료를 통합할 것이라고 발표했습니다. 현재 위치에서도 이미 이 서비스를 제공하고 있습니다. TPE는 환자의 혈장을 제거하고 교체하기 위해 아페레시스 기계를 사용하여 혈류 내 유해 물질을 목표로 합니다.
클리닉은 조혈모세포 이식(HSCT)에 사용되는 동일한 장비를 활용하여 아디아 메드를 이 기술을 보유한 미국 내 세 개의 클리닉 네트워크 중 하나로 만듭니다. 이 치료법은 다양한 상태에 대해 희망적인 결과를 보여주며, 알츠하이머병을 포함하여 연구에 따르면 TPE와 알부민 대체가 결합되면 인지 저하를 늦출 수 있습니다.
TPE의 전국 평균 비용은 환자당 $4,000에서 $6,000 사이입니다. 플로리다의 65세 이상 450만 명 이상의 은퇴자 인구로 인해 아디아 메드는 특히 노화 관련 질환 및 자가면역 질환에 대한 상당한 시장 잠재력을 보고 있습니다.
Adia Nutrition (OTC: ADIA) a annoncé que sa filiale, Adia Med, intégrera le traitement d'Échange Plasma Thérapeutique (TPE) dans tous les futurs emplacements de cliniques complètes aux États-Unis, avec son emplacement actuel offrant déjà ce service. Le TPE utilise des machines d'apheresis pour retirer et remplacer le plasma des patients, ciblant les substances nocives dans le sang.
Les cliniques utiliseront le même équipement que celui utilisé pour la transplantation de cellules souches hématopoïétiques (HSCT), faisant d'Adia Med l'un des trois seuls réseaux cliniques aux États-Unis à disposer de cette technologie. Ce traitement montre des promesses pour diverses conditions, y compris la maladie d'Alzheimer, où des études indiquent que le TPE combiné à un remplacement d'albumine peut ralentir le déclin cognitif.
Le coût moyen national du TPE varie de 4 000 à 6 000 dollars par patient. Avec la grande population de retraités de la Floride, qui compte plus de 4,5 millions de résidents âgés de 65 ans et plus, Adia Med voit un potentiel de marché significatif, en particulier pour les conditions liées à l'âge et les troubles auto-immuns.
Adia Nutrition (OTC: ADIA) hat angekündigt, dass ihre Tochtergesellschaft Adia Med die therapeutische Plasmapherese (TPE) in allen zukünftigen voll ausgestatteten Klinikstandorten in den Vereinigten Staaten integrieren wird, wobei der aktuelle Standort bereits diesen Service anbietet. TPE verwendet Apherese-Maschinen, um das Plasma der Patienten zu entfernen und zu ersetzen, wobei schädliche Substanzen im Blutkreislauf gezielt werden.
Die Kliniken werden dieselbe Ausrüstung nutzen, die für die hämatopoetische Stammzelltransplantation (HSCT) verwendet wird, wodurch Adia Med zu einem von nur drei Kliniknetzwerken in den USA mit dieser Technologie wird. Die Behandlung zeigt vielversprechende Ergebnisse für verschiedene Erkrankungen, einschließlich Alzheimer, wo Studien darauf hinweisen, dass TPE in Kombination mit Albumin-Ersatz den kognitiven Rückgang verlangsamen kann.
Die nationalen Durchschnittskosten für TPE liegen zwischen 4.000 und 6.000 US-Dollar pro Patient. Angesichts der großen Rentnerbevölkerung Floridas mit über 4,5 Millionen Einwohnern im Alter von 65 Jahren und älter sieht Adia Med erhebliches Marktpotenzial, insbesondere für altersbedingte Erkrankungen und Autoimmunerkrankungen.
- Current clinic already generating revenue from TPE treatments
- One of only three clinic networks in U.S. with this specialized technology
- Large target market with 4.5M Florida residents aged 65+
- TPE treatment costs of $4,000-$6,000 per patient indicate strong revenue potential
- Insurance coverage already approved for some Alzheimer's applications
- Significant competition from two other clinic networks with similar technology
- High treatment costs may limit accessibility for uninsured patients
- Success depends on expansion to new clinic locations not yet established
Winter Park, Florida--(Newsfile Corp. - March 17, 2025) - Adia Nutrition (OTC Pink: ADIA), a leader in innovative healthcare solutions, is thrilled to announce that its subsidiary, Adia Med, will ensure that all future full clinic locations across the United States will offer Therapeutic Plasma Exchange (TPE), with its current location already offering this advanced treatment as of today. These full clinics, which will also perform Hematopoietic Stem Cell Transplantation (HSCT) for various conditions using state-of-the-art apheresis machines, will integrate TPE into their offerings, leveraging the same cutting-edge equipment. This forward-thinking expansion will unlock a wide range of applications, including potential benefits for Alzheimer's disease, reinforcing Adia Med's commitment to pioneering patient care.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243472_70824-9959585.jpeg
TPE, a procedure that utilizes an apheresis machine to remove and replace a patient's plasma, will target harmful substances—such as autoantibodies, immune complexes, and toxins—in the bloodstream, offering hope for numerous conditions, including neurodegenerative diseases like Alzheimer's. With all future Adia Med full clinics set to utilize apheresis technology for HSCT, they will seamlessly adopt TPE, maximizing the potential of this sophisticated equipment. The current Adia Med location, now offering TPE, marks the first step in this transformative vision.
"We are excited to announce that all our future full clinics will provide TPE, a treatment with immense potential to change lives, including for those affected by Alzheimer's," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care. As one of just three clinic networks in the U.S. with this technology, we will continue to lead the charge in advanced medical solutions."
Studies have highlighted the promising benefits and versatility of TPE across various conditions, including Alzheimer's disease. A study published in Alzheimer's & Dementia explored the AMBAR trial, which showed that TPE combined with albumin replacement slowed cognitive and functional decline in patients with mild-to-moderate Alzheimer's, suggesting that removing amyloid-beta proteins and other toxic plasma components could play a key role in disease management. Notably, insurance has already covered TPE for Alzheimer's applications in some cases, reflecting growing recognition of its potential.
Additionally, research in Transfusion and Apheresis Science demonstrated TPE's ability to reduce mortality in moderate-to-critical COVID-19 patients, with a risk ratio of 0.41 (
The national average cost for TPE ranges from
Patients and healthcare providers eager to explore TPE and other services at Adia Med's clinics can visit www.adiamed.com or contact 321-788-0850 for more information as these offerings roll out.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243472
FAQ
What is the cost of Therapeutic Plasma Exchange (TPE) treatment at Adia Med (ADIA)?
How effective is TPE treatment for Alzheimer's disease according to Adia Med's (ADIA) announcement?
What medical conditions will Adia Med's (ADIA) TPE treatment target?
When will Adia Med (ADIA) begin offering TPE treatment at its locations?
